Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

Part of Osteoporosis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Postmenopausal Osteoporosis

60 trials tracked for Postmenopausal Osteoporosis: 41 in phase 3 or 4 and 13 with published results. The most-cited published study has 589 citations.

60Trials tracked
41Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 14 Phase 3 27 Phase 2 8 Phase 1 5 Other / NA 6
  1. Phase 4 VERtebral Fracture Treatment Comparisons in Osteoporotic Women Completed · 589 cited
  2. Phase 3 An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women Completed · 476 cited
  3. Phase 3 Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis Completed · 204 cited
  4. Phase 3 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis Completed · 168 cited
  5. Phase 4 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis Completed · 161 cited
  6. Phase 4 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed · 70 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed · 47 cited
  2. Phase 3 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Completed · 40 cited
  3. Phase 3 A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis Completed · 28 cited
  4. Phase 3 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis Completed · 22 cited
  5. Phase 3 A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis Completed · 12 cited
  6. Phase 4 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed · 8 cited
  7. Phase 3 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND Completed · 3 cited
  8. Phase 4 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed
  9. Phase 4 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed
  10. Phase 4 The Effects of Potassium Citrate on Bone Metabolism Completed
  11. Phase 4 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed
  12. Phase 4 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Completed
  13. Phase 4 Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) Completed
  14. Phase 4 Preventing Osteoporosis Using Denosumab Completed
  15. Phase 4 A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide Completed
  16. Phase 4 Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) Completed
  17. Phase 4 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed
  18. Phase 3 Denosumab China Phase III Study Completed
  19. Phase 3 A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis Completed
  20. Phase 3 A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis Completed
  21. Phase 3 A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis Completed
  22. Phase 3 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Completed
  23. Phase 3 A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis Completed
  24. Phase 3 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® Completed
  25. Phase 3 A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  26. Phase 3 Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis Completed
  27. Phase 3 A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women Completed
  28. Phase 3 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates Completed
  29. Phase 3 A Study of Monthly Risedronate for Osteoporosis Completed
  30. Phase 3 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  31. Phase 3 Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women Completed
  32. Phase 3 Study of Transitioning From Alendronate to Denosumab Completed
  33. Phase 3 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab Completed
  34. Phase 3 Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis Completed
  35. Phase 3 A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Completed
  36. Phase 2 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women Completed
  37. Phase 2 Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) Completed
  38. Phase 2 Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women Completed
  39. Phase 2 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed
  40. Phase 2 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed
  41. Phase 2 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Completed
  42. Phase 2 Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women Completed
  43. Phase 2 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Completed
  44. Phase 1 A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Postmenopausal Osteoporosis: what the trials found

New clinical evidence identifies ENZ215 as a treatment for postmenopausal osteoporosis 1.

Teriparatide significantly reduces the incidence of new vertebral fractures (p=0.000094), pooled new and worsening vertebral fractures (p=0.000075), and pooled clinical vertebral and non-vertebral fragility fractures (p=0.000869) 2.

Denosumab is associated with significant increases in spine bone mineral density (BMD) 4 and improvements in total hip BMD 6 and spine BMD 6.

Romosozumab demonstrates significant efficacy in reducing the incidence of new vertebral fractures at 12 months (p<0.001) and 24 months (p<0.001), as well as clinical fractures at 12 months (p=0.008) 18. It also significantly increases BMD at the lumbar spine, total hip, and femoral neck [16, 21].

Abaloparatide is associated with significant increases in mineralizing surface/bone surface (MS/BS) in the cancellous envelope 20, as well as significant increases in lumbar spine, total hip, and femoral neck BMD at 12 months 22.

Alendronate combinations show significant improvements in lumbar spine BMD at both 6 and 12 months 13 and significantly higher gains in total hip, femoral neck, and lumbar spine BMD compared to other cohorts 17. Alendronate with cholecalciferol was associated with a reduction in patients with serum 25-hydroxyvitamin D below deficiency levels (p<0.0001) and significant changes in Serum PTH 15.

Ibandronate is associated with high patient adherence rates (98.5%) and high scores in patient satisfaction surveys 11. Patients also showed a preference for once-monthly dosing over once-weekly dosing based on convenience of administration (p<0.0001) 9.

Placebo groups showed significant increases in lumbar spine BMD compared to other cohorts at 6 and 12 months 12, while a separate placebo study showed significantly lower rates of new vertebral fractures compared to an intervention group 19.

Recent results — preliminary, needs further review

  • ENZ215 is identified as a new treatment for postmenopausal osteoporosis 1.

For the clinician treating this condition

  • Teriparatide, Romosozumab, and Abaloparatide are associated with significant reductions in fracture incidence or substantial increases in bone mineral density across multiple sites.
  • Denosumab and Alendronate (with various co-treatments) provide statistically significant improvements in spine and hip BMD.
  • Ibandronate is associated with high patient satisfaction and adherence, particularly when administered in a once-monthly dosing regimen.

AI synthesis of 14 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women
Diabetes & Endocrinology Cohort
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women Better nutrition linked to lower osteoporosis risk in women with diabetes
This retrospective observational cohort study of 324 postmenopausal women with type 2 diabetes found that a higher Geriatric Nutritional Ris…
A simple nutrition score may help spot osteoporosis risk in women with type 2 diabetes, new hospital data suggests.
Frontiers Apr 22, 2026

Research across Osteoporosis

Related studies from across the Osteoporosis family.

Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management
Orthopedics & Sports Medicine Sys. Review
Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management Scoliosis and Osteoporosis Research Trends Mapped Over 20 Years
A comprehensive bibliometric analysis of over 1,000 publications highlights a significant shift toward bone quality assessment and risk stra…
A new review maps 20 years of scoliosis and osteoporosis research, revealing a shift toward bone quality and surgical outcomes.
Frontiers Jul 25, 2026
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis
OB/GYN & Women's Health Sys. Review
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis Gut bacteria may help prevent osteoporosis in older women
This systematic review explores how gut microbiota-based interventions, including probiotics and prebiotics, may impact bone health in postm…
A new review suggests probiotics and other gut-focused treatments could help protect bone health in postmenopausal women.
Frontiers Jul 4, 2026
The osteoimmune-brain axis links systemic inflammation and bone hormones to neurodegenerative pathology
Allergy & Immunology Sys. Review
The osteoimmune-brain axis links systemic inflammation and bone hormones to neurodegenerative pathology Immune system may link bone health and brain disease
This systematic review examines the role of the osteoimmune-brain axis, where the immune system mediates skeletal and cerebral pathology thr…
A new look at the body's immune system suggests a link between bone health and conditions like Alzheimer's and dementia.
Frontiers Jun 24, 2026
Locking plate fixation and arthroplasty are key treatments for osteoporotic proximal humeral fractures
Orthopedics & Sports Medicine Sys. Review
Locking plate fixation and arthroplasty are key treatments for osteoporotic proximal humeral fractures Mainstream Treatments for Complex Osteoporotic Shoulder Fractures
This systematic review summarizes mainstream treatments for elderly patients with complex osteoporotic proximal humeral fractures. Strategie…
New evidence helps doctors choose the best surgical options, such as locking plates or joint replacements, for elderly patients with complex…
Frontiers Jun 23, 2026
Circadian misalignment associated with increased risk of osteoporosis, sarcopenia, and osteoarthritis
Nutrition & Obesity Medicine Sys. Review
Circadian misalignment associated with increased risk of osteoporosis, sarcopenia, and osteoarthritis Circadian Disruption Linked to Bone and Muscle Loss
This narrative review examines the impact of circadian disruption on musculoskeletal health, specifically regarding bone loss, muscle protei…
Shift work and irregular eating may harm bones and muscles. A new review explains how.
Frontiers Jun 22, 2026
Chinese botanical drugs may improve bone metabolism by modulating the gut-bone axis in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Chinese botanical drugs may improve bone metabolism by modulating the gut-bone axis in osteoporosis Chinese Botanical Drugs May Help Manage Osteoporosis via Gut Health
This systematic review examines how Chinese botanical drugs (CBDs) influence bone metabolism through gut microbiota remodeling and intestina…
New research suggests that Chinese botanical drugs may help manage osteoporosis by improving gut health and the connection between the gut a…
Frontiers Jun 20, 2026
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis
Allergy & Immunology Sys. Review
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis Immune Cells and Signaling Pathways Influence Bone Health in Osteoporosis
This narrative review synthesizes the role of CD8+ T cells and related cytokines like IFN-gamma, CCL5, and IL-33 in bone metabolism. The aut…
New research highlights how specific immune cells and signaling pathways may play a dual role in protecting or promoting bone loss in osteop…
Frontiers Jun 12, 2026
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates
Drug Pipeline Sys. Review
Novel osteoporosis therapies targeting osteoclast fusion and polarization show promise beyond bisphosphonates New osteoporosis treatments target bone-eating cells more safely
This narrative review examines emerging therapeutic strategies that target osteoclast fusion and polarization, including DC-STAMP/OC-STAMP n…
Future osteoporosis drugs may work by blocking the fusion of bone-destroying cells, offering a safer alternative to current treatments.
Frontiers Jun 5, 2026
Physical exercise therapy may support osteosarcopenia management in elderly patients according to this narrative review
Geriatrics & Aging Sys. Review
Physical exercise therapy may support osteosarcopenia management in elderly patients according to this narrative review Exercise may help fight bone and muscle loss in aging
This narrative review discusses physical exercise therapy for osteosarcopenia in the elderly population. The authors outline potential benef…
A new review suggests physical exercise could slow bone and muscle loss in older adults with osteosarcopenia.
Frontiers Jun 4, 2026
Network meta-analysis reveals optimal aerobic exercise frequency and intensity for improving bone mineral density in osteoporosis patients
Diabetes & Endocrinology Meta-analysis
Network meta-analysis reveals optimal aerobic exercise frequency and intensity for improving bone mineral density in osteoporosis patients Network meta-analysis finds aerobic exercise improves bone density in osteoporosis patients
A comprehensive network meta-analysis of 2,183 participants demonstrates that aerobic exercise significantly boosts bone mineral density acr…
A network meta-analysis of 2,183 participants shows aerobic exercise improves bone density better than control, with specific intensity and …
Frontiers Jun 3, 2026
Drug-induced osteoporosis mechanisms and gut microbiota links remain largely unresolved for most medication classes
Orthopedics & Sports Medicine Sys. Review
Drug-induced osteoporosis mechanisms and gut microbiota links remain largely unresolved for most medication classes Many common medicines might change gut bacteria and affect bone strength in older adults
This narrative review examines the association between medications such as glucocorticoids and aromatase inhibitors and gut microbiota alter…
Some drugs like antidepressants and seizure medicines can alter gut bacteria. Scientists are still studying if these changes hurt bones or c…
Frontiers Jun 1, 2026
Gut microbiome metabolites regulate bone health via SCFAs, bile acids, and tryptophan pathways
Orthopedics & Sports Medicine Sys. Review
Gut microbiome metabolites regulate bone health via SCFAs, bile acids, and tryptophan pathways Multi-omics approaches reveal new links between gut microbes and bone health
This narrative review synthesizes evidence that gut microbiome metabolites—SCFAs, bile acids, and tryptophan derivatives—regulate bone remod…
A narrative review suggests gut microbes may influence bone conditions like osteoporosis and osteoarthritis through specific metabolic pathw…
Frontiers May 29, 2026